Topical progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women.

Authors: Stephenson K, Price C, Kurdowska A, Neuenschwander P, Stephenson J, Pinson B,  Stephenson D, Alfred D, Krupa A, Mahoney D, Zava D, Bevan M.

Publication Year: 2004

Citation: Presented at the 46th Annual Meeting of the American Society of Hematology, San Diego, December 4-7, 2004.  Blood 2004; 104(11 Pt 1):414b-415b(Abstract 5318).

No change in any of the thrombotic or inflammatory markers studied (total factor VII:C, factor VIIa, factor V, fibrinogen, antithrombin, PAI-1, CRP, TNF?, and IL-6) was observed, despite significant symptomatic improvement compared to placebo, in 30 women receiving 20 mg/day progesterone cream for 4 weeks.  This finding indicates a lack of potential adverse effects of progesterone on the cardiovascular system, particularly with respect to risk of coronary artery disease and stroke. The authors conclude that administration of topical progesterone cream at a daily dose of 20 mg significantly relieves menopausal symptoms in postmenopausal women without adversely altering prothrombotic potential. Since the thrombotic complications that are typically observed with conventional hormone replacement therapy, and have led to an increase in stroke,  do not seem to occur with topical progesterone, this treatment should be seriously considered as an effective and safe alternative clinical therapy for women suffering from menopausal symptoms.